1. The aim of the study was to determine the carbachol and albuterol responsiveness in treated and untreated asthmatic and allergic children exposed to environmental tobacco smoke assessed by urinary cotinine measurements. 2. Forty-six asthmatic and allergic children with normal spirometric values were recruited.
The doubling dose, concentration of carbachol producing a 2-fold increase in specific airway resistance (SRaw) was determined and 200 mug of albuterol were administered via a Volumatic spacer.
The percentage of bronchodilatation was defined as the difference between the largest obtained SRaw and the post-bêta2 SRaw divided by the largest SRaw.
Data were compared by a Mann-Whitney U-test. 3. The 23 children with a high urinary cotinine, compared with the 23 children without urinary cotinine, had a decreased doubling dose (108.2± 14.7 mug versus 160.9+19.5 mug ; P=0.04) and an increased percentage of bronchodilatation (74.8± 1.4% versus 68.8+1.8% ; P=0.03).
A prophylactic anti-inflammatory treatment induced a weaker bronchial reactivity to carbachol and a slightly greater bronchodilatation in children exposed to environmental tobacco smoke. 4. Environmental tobacco smoke increases bronchial reactivity in asthmatic and allergic children.
This effect might be reduced by anti-inflammatory therapy.
The bronchodilator response may be enhanced in exposed children and may be caused by one or several direct interactions between tobacco smoke compounds and albuterol.
Mots-clés Pascal : Tabagisme passif, Impact environnement, Exploration clinique, Asthme, Allergie, Traitement, Carbachol, Salbutamol, Chimiothérapie, Interaction, Bronchodilatation, Enfant, Homme, Toxicologie, Appareil respiratoire pathologie, Bronchopneumopathie obstructive, Immunopathologie, Parasympathomimétique, Antiglaucomateux, Myotique
Mots-clés Pascal anglais : Passive smoking, Environment impact, Clinical investigation, Asthma, Allergy, Treatment, Carbachol, Salbutamol, Chemotherapy, Interaction, Bronchodilation, Child, Human, Toxicology, Respiratory disease, Obstructive pulmonary disease, Immunopathology, Parasympathomimetic, Antiglaucomatous agent, Myotic
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0410660
Code Inist : 002B02D. Création : 25/01/1999.